Less is more: Antibiotics at the beginning of life.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37105958.
- Also identified by DOI 10.1038/s41467-023-38156-7 and PMC identifier 10134707.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Antibiotic exposure at the beginning of life can lead to increased antimicrobial resistance and perturbations of the developing microbiome. Early-life microbiome disruption increases the risks of developing chronic diseases later in life. Fear of missing evolving neonatal sepsis is the key driver for antibiotic overtreatment early in life. Bias (a systemic deviation towards overtreatment) and noise (a random scatter) affect the decision-making process. In this perspective, we advocate for a factual approach quantifying the burden of treatment in relation to the burden of disease balancing antimicrobial stewardship and effective sepsis management.
Medical subject headings
- Infant, Newborn
- Humans
- Anti-Bacterial Agents
- Anti-Bacterial Agents/pharmacology
- Anti-Bacterial Agents/therapeutic use
- Beginning of Human Life
- Sepsis
- Sepsis/drug therapy
- Neonatal Sepsis
- Neonatal Sepsis/drug therapy
- Antimicrobial Stewardship